Medication info
New Glyphield Tablets 2mg (Glymepiride)

New Glyphield Tablets 2mg (Glymepiride)

Prescription medicationTabletOral
Ingredient · strength
Glimepiride›2mg / 1 tablet
Manufacturer / importer
Anguk Newpharm Co., Ltd.
Appearance
Green oval-shaped tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201603555 · Approved 2016.06.17 · Insurance code 053600440

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose should be individualized for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received medication, start treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. Generally, there is little additional effect with doses above 4 mg, although some patients have shown better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic medicine. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered in the event of weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose relationship between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is advisable to follow the instructions given under Initial dose. That is, treatment may be started at 1 mg once daily, with dose adjustments at 1 ~ 2-week intervals. The potency and duration of action of the previously administered medicine should be taken into account. 4) Dose monitoring Blood glucose and/or urine glucose levels should be measured regularly during treatment with this medicine; regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Hypoglycemia may recur despite successful initial management during treatment with sulfonylureas. Therefore, patients should be carefully monitored. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization may sometimes be necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and start insulin at a low dose, increasing it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to identify the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may be increased. Appropriate precautions should be taken.

Ingredients

Manufacturer
Anguk Newpharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to assist in blood sugar control for patients with type 2 diabetes. It is primarily given as a supplement to dietary and exercise therapy, and if blood sugar is not sufficiently controlled, it may be used in combination with other oral hypoglycemic agents or insulin. It is particularly effective to use this medication alongside sulfonylureas or metformin when control is difficult. This aids in blood sugar management to improve diabetes treatment.

How to take

Adult dose

The dose should be individualized for each patient. Swallow without chewing with at least 1/2 cup of water. This medicine is administered orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received medication, start treatment with 1 mg of glimepiride once daily. If necessary, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. Generally, there is little additional effect with doses above 4 mg, although some patients have shown better metabolic control when the dose was increased to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic medicine. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered in the event of weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose relationship between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is advisable to follow the instructions given under Initial dose. That is, treatment may be started at 1 mg once daily, with dose adjustments at 1 ~ 2-week intervals. The potency and duration of action of the previously administered medicine should be taken into account. 4) Dose monitoring Blood glucose and/or urine glucose levels should be measured regularly during treatment with this medicine; regular measurement of glycated hemoglobin (HbA1c) is also recommended. In general, hypoglycemia is promptly controlled by immediate intake of sugar. Hypoglycemia may recur despite successful initial management during treatment with sulfonylureas. Therefore, patients should be carefully monitored. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization may sometimes be necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and start insulin at a low dose, increasing it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, capillary blood glucose should be monitored daily whenever possible. The insulin dose should be adjusted periodically while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, addition of metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to identify the minimum effective dose of each medicine for blood glucose control. There is a risk of hypoglycemia when this medicine is administered with metformin, and the risk may be increased. Appropriate precautions should be taken.

Precautions

This medication must not be used in patients with type 1 diabetes, diabetic ketoacidosis, or those in a state of coma. It should also not be administered to individuals allergic to this medication or sulfonylureas, or sulfonamides. Patients with severe liver or kidney impairment should not use this medication and should switch to insulin therapy. Women who are pregnant, may become pregnant, or are breastfeeding should not take this medication. Patients with severe infections, pre- or post-surgery, or trauma may require insulin therapy. Patients with gastrointestinal disorders should be cautious as malabsorption may increase the risk of hypoglycemia. Individuals with lactose intolerance or specific genetic metabolic disorders should not take this medication. During the initial dosing phase, there is an increased risk of hypoglycemia, so blood sugar should be checked frequently, and symptoms of hypoglycemia should be observed. Particularly for the elderly, those with poor nutritional status or irregular eating habits, and patients with poor liver or kidney function, careful administration is necessary. Excessive alcohol consumption or taking other medications can also affect blood sugar control, so caution is advised. Symptoms of hypoglycemia include headache, fatigue, dizziness, confusion, drowsiness, so if these appear, immediate intake of sugar is required. In severe cases, loss of consciousness or seizures may occur, necessitating immediate medical assistance. Visual disturbances, gastrointestinal symptoms, liver function abnormalities, blood abnormalities, and allergic reactions may also occur; consult a physician if any abnormal symptoms arise. This medication should be taken regularly, and dietary plans and exercise should be combined for optimal blood sugar control. The quickest response to hypoglycemia is to consume sugar; artificial sweeteners without sugar are ineffective. When receiving treatment at other hospitals or pharmacies, it is essential to inform them of the use of this medication and the diabetic condition. In stressful situations such as surgery or infections, a temporary switch to insulin therapy may be necessary. Start with a small dose and confirm effectiveness through blood and urine tests, adjusting as necessary. This medication may affect driving or operating machinery, so caution is warranted. There may be interactions with specific medications, so inform your healthcare provider of any other medications being taken. Women who are pregnant or breastfeeding should not use this medication and should switch to insulin therapy for safety. Safety and efficacy in children under 18 years have not been established. Elderly patients may need dosage adjustments due to decreased kidney function. In case of overdose, hypoglycemia may worsen, so immediate visit to a medical institution for proper treatment is necessary. This medication should be kept out of reach of children and stored in its original container.

Side effects

  • Hypoglycemia
  • headache
  • severe hunger
  • nausea
  • vomiting
  • fatigue
  • sleep
  • sleep disorders
  • anxiety
  • aggression
Show 68 more
  • decreased concentration
  • decreased agility or energy
  • depression
  • confusion
  • speech disturbances
  • aphasia
  • visual impairment
  • tremors
  • partial paralysis
  • sensory disturbances
  • dizziness
  • weakness
  • loss of self-control
  • temporary mental confusion
  • seizures
  • drowsiness
  • loss of consciousness
  • coma
  • shallow breathing
  • bradycardia
  • sweating
  • cold and moist skin
  • tachycardia
  • hypertension
  • palpitations
  • angina
  • venous arrhythmias
  • blurred vision
  • fullness in the upper abdomen
  • pressure
  • abdominal pain
  • diarrhea
  • elevated liver enzymes
  • abnormal liver function
  • bile secretion disorders
  • jaundice
  • hepatitis
  • thrombocytopenia
  • leukopenia
  • hemolytic anemia
  • erythrocytopenia
  • neutropenia
  • agranulocytosis
  • pancytopenia
  • itching
  • hives
  • rash
  • respiratory distress
  • hypotension
  • shock
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • allergic vasculitis
  • photosensitivity reactions of the skin
  • decreased serum sodium concentration
  • taste disturbances
  • hair loss
  • weight gain
  • dizziness
  • abnormal liver function
  • abdominal pain
  • arthralgia
  • dyspepsia
  • facial edema
  • erectile dysfunction
  • facial flushing
  • gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius, avoiding extremely hot or cold places.

Appearance and packaging

Appearance

Green oval-shaped tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.